Takeda Pharmaceutical Income Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Year	2022	2021	2020	2019	2018	2017	2016
Revenue	4,027,478	3,569,006	3,197,812	3,291,188	2,097,224	1,770,531	1,732,051
Revenue Growth (YoY)	12.85%	11.61%	-2.84%	56.93%	18.45%	2.22%	-
Cost of Revenue	1,244,072	1,106,846	994,308	1,089,764	651,729	495,921	558,755
Gross Profit	2,783,406	2,462,160	2,203,504	2,201,424	1,445,495	1,274,610	1,173,296
Selling, General & Admin	997,309	886,361	875,663	964,737	717,599	628,106	619,061
Research & Development	633,325	526,087	455,833	492,381	368,298	325,441	312,303
Other Operating Expenses	662,266	588,867	362,739	643,898	121,913	79,274	86,065
Operating Expenses	2,292,900	2,001,315	1,694,235	2,101,016	1,207,810	1,032,821	1,017,429
Operating Income	490,506	460,845	509,269	100,408	237,685	241,789	155,867
Interest Expense / Income	169,698	166,607	248,631	165,006	83,289	31,928	23,249
Other Expense / Income	-54,261	-8,226	-105,431	-3,795	26,672	-7,522	-10,155
Pretax Income	375,069	302,464	366,069	-60,803	127,724	217,383	142,773
Income Tax	58,052	72,405	-9,936	-105,044	-7,468	30,497	27,833
Net Income	317,017	230,059	376,005	44,241	135,192	186,886	114,940
Net Income Growth	37.80%	-38.81%	749.90%	-67.28%	-27.66%	62.59%	-
Shares Outstanding (Basic)	1,550	1,563	1,558	1,565	783	-	-
Shares Change	-0.83%	0.36%	-0.46%	99.75%	-	-	-
EPS (Basic)	102.14	73.57	120.36	14.21	70.31	119.67	73.58
EPS (Diluted)	100.97	72.94	119.48	14.13	69.91	118.78	73.13
EPS Growth	38.44%	-38.96%	745.88%	-79.80%	-41.14%	62.42%	-
Free Cash Flow	1,023,427	1,142,091	1,147,865	782,016	346,428	343,697	243,083
Free Cash Flow Per Share	330.06	365.27	368.43	249.84	221.08	-	-
Dividend Per Share	-	-	-	-	-	0.806	0.791
Dividend Growth	-	-	-	-	-	1.90%	-
Gross Margin	69.11%	68.99%	68.91%	66.89%	68.92%	71.99%	67.74%
Operating Margin	12.18%	12.91%	15.93%	3.05%	11.33%	13.66%	9.00%
Profit Margin	7.87%	6.45%	11.76%	1.34%	6.45%	10.56%	6.64%
Free Cash Flow Margin	25.41%	32.00%	35.90%	23.76%	16.52%	19.41%	14.03%
Effective Tax Rate	15.48%	23.94%	-2.71%	-	-5.85%	14.03%	19.49%
EBITDA	1,209,167	1,052,222	1,174,371	687,852	458,704	431,438	337,448
EBITDA Margin	30.02%	29.48%	36.72%	20.90%	21.87%	24.37%	19.48%
Depreciation & Amortization	664,400	583,151	559,671	583,649	247,691	182,127	171,426
EBIT	544,767	469,071	614,700	104,203	211,013	249,311	166,022
EBIT Margin	13.53%	13.14%	19.22%	3.17%	10.06%	14.08%	9.59%

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).